• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.
【24h】

T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.

机译：多发性硬化症缓解无反应患者中的T细胞疫苗接种。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Myelin autoreactive T cells are involved in the pathogenesis of multiple sclerosis (MS) and lead to propagation of the disease. We evaluated the efficacy of T cell vaccination (TCV) therapy for patients with aggressive relapsing-remitting MS who failed to respond to immunomodulatory treatments. Twenty nonresponders relapsing-remitting MS patients were immunized with autologous attenuated T cell lines after activation with synthetic myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) encephalitogenic peptides. Each patient received three vaccinations in 6- to 8-week intervals. Annual relapse rate decreased from 2.6 to 1.1, P = 0.026. Neurological disability stabilized as compared with the 2- and 1-year pretreatment progression rates. Significant reduction in the number and volume of active lesions, as well as reduction in T2 lesion burden, was demonstrated by quantitative MRI analysis. No serious adverse events were observed. Our findings suggest that TCV has beneficial clinical effects in MS patients who, in spite of immunomodulatory treatments, continue to deteriorate. TCV could serve as a potential alternative therapy for this subgroup of nonresponders patients.
机译：髓磷脂自身反应性T细胞参与多发性硬化症（MS）的发病机理，并导致疾病传播。我们评估了T细胞疫苗接种（TCV）治疗对未能对免疫调节治疗产生反应的侵袭性复发缓解型MS患者的疗效。用合成的髓鞘碱性蛋白（MBP）和髓鞘少突胶质细胞糖蛋白（MOG）致脑源肽激活后，用自体减毒T细胞株免疫20名无反应者复发-缓解型MS患者。每位患者在6至8周的间隔内接受了3次疫苗接种。年复发率从2.6降至1.1，P = 0.026。与2年和1年的预处理进展率相比，神经功能障碍稳定了。定量MRI分析显示，活动性病变的数量和体积显着减少，T2病变负担减少。没有观察到严重的不良事件。我们的研究结果表明，TCV在MS患者中具有有益的临床效果，尽管采用了免疫调节治疗，但仍继续恶化。 TCV可以作为这一无反应患者亚组的潜在替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号